Marker Therapeutics (MRKR) Research & Development (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Research & Development of $2.8 million for Q1 2026, down 9.34% year-over-year from $3.1 million in Q1 2025, and up 32.79% quarter-over-quarter from $2.1 million in Q4 2025.
Marker Therapeutics (MRKR) Research & Development (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Research & Development for 17 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 9.34% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $11.5 million (down 17.98% YoY), while the FY2025 annual figure was $11.8 million, down 12.39% from the prior year.
- Research & Development rose to $2.8 million in Q1 2026 per MRKR's latest filing, from $2.1 million in the prior quarter.
- Across five years, Research & Development topped out at $7.0 million in Q1 2022 and bottomed at $2.0 million in Q3 2023.
- Historically, Research & Development has averaged $3.2 million across 5 years, with a median of $2.8 million in 2026.
- Annual changes were most pronounced in 2022 — Research & Development plunged 72.78% — and 2024, when it surged 94.33%.
- Marker Therapeutics' Research & Development stood at $2.2 million in 2022, then climbed by 19.93% to $2.6 million in 2023, then soared by 94.33% to $5.1 million in 2024, then tumbled by 57.91% to $2.1 million in 2025, then surged by 32.79% to $2.8 million in 2026.
- Business Quant data shows MRKR's Research & Development at $2.8 million in Q1 2026, $2.1 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 4.18 Mn |
| Mar 31, 2025 | 3.14 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Sep 30, 2024 | 3.47 Mn |
| Jun 30, 2024 | 2.34 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 2.38 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 2.92 Mn |
| Mar 31, 2022 | 7.03 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Sep 30, 2021 | 6.78 Mn |
| Jun 30, 2021 | 7.35 Mn |